Xspray Pharma: HyNap-Dasa, a no-brainer for BMS?

Research Update

2020-07-13

07:30

We have delved deeper in historical patent litigations with focus on amorphous vs crystalline candidates, and highlight a recent case which ended in a settlement between the generic and original company. These findings reinforce our belief that a deal could be reached shortly after the study data. Thus, we revalue our estimates, which leads to higher valuations.

JS

LS

Jakob Svensson

Ludvig Svensson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.